Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
See what results to expect from zero based budgeting and how to monitor progress with clear, actionable metrics.
19,375 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
As the auto industry pivots toward electric and software-enabled services, the path for Ford stock over the next deca...
A Manhattan federal judge rejected Binance’s bid to compel private arbitration, allowing a class-action alleging unre...
Bitcoin remains above $66,000 as March begins, with analysts weighing a bitcoin high-stakes march: $120k scenario ami...
Bitcoin vaulted toward $69,000 in a tight hour, as investors priced in geopolitical headlines and an impending Iran-r...
Digital asset funds snapped a five-week bleed with a $1 billion inflow, led by Bitcoin and Ethereum, signaling a caut...
A growing crime trend links revenge plots to cryptocurrency payments. This article explains how digital money helped ...
A rising figure in Iran’s shadow government, Mojtaba Khamenei is fueling a debate over who will lead and how the econ...
PulteGroup has teamed up with SitecoreAI to unify its marketing, sales, and CRM systems, aiming for a seamless, perso...
Claude AI projects a multi-year rally for XRP, SOL, and ADA, with end-2026 targets that would mark fresh highs amid i...
Berkshire Hathaway has resumed stock buybacks, purchasing $15 million of its own shares. CEO Greg Abel personally bou...
A wave of headlines claims cramer says trillion-dollar stocks are the must-watch trend. This article breaks down what...